Filing Flows

Filing Flows › Integra Lifesciences Holdings (IART) › Q3 2026

Integra Lifesciences Holdings (IART) Q3 2026 earnings results (third quarter 2026)

10-Q filed Oct 23, 2026

Integra Lifesciences Holdings (IART) reported revenue of $411M for the third quarter 2026 (Q3 2026), +2% from a year earlier and -2% from the quarter before. Operating margin was 4.6%, net earnings $14.9M (3.6% of revenue).

Revenue$411M
Year over year+2%
Quarter over quarter-2%
Operating margin4.6%
Net earnings$14.9M

Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart follows the revenue to costs, profit and cash.

Q3 2026AmountQ/QY/Y
Revenue$411M-2%+2%
Operating profit$18.9M-2%+61%
Net earnings$14.9M+231%—
Operating cash flow$96.0M+321%+135%
Free cash flow$85.7M—+233%

What changed

Revenue was $411.2M in Q3 2026, up 2% year over year and down 2% from the previous quarter. Specialty Surgery was the largest line at 74% of revenue. Specialty Surgery added $11.5M year over year (up 4%), 127% of the total change. Tissue Reconstruction declined 2%.

Operating profit was $18.9M, a 4.6% margin (up 1.7 points year over year). Of the extra revenue versus Q3 2025, 78% reached operating profit, above the 3% margin then. Total costs grew 1% against revenue growth of 2%. Net earnings were $14.9M. The effective tax rate was 5.2%.

Operating cash flow was $96.0M (up 135% year over year), 646% of net earnings. Non-cash charges added back $2.9M of share-based compensation. Working capital and other items added $78.2M. After purchases of property and equipment ($10.2M), free cash flow as the company reports it was $85.7M.

Questions

What was Integra Lifesciences Holdings' revenue in the third quarter 2026?

Integra Lifesciences Holdings (IART) reported revenue of $411M for the third quarter 2026 (Q3 2026), +2% from a year earlier and -2% from the quarter before.

Was Integra Lifesciences Holdings profitable in the third quarter 2026?

Operating profit was $18.9M (4.6% of revenue) and net earnings $14.9M.

Open the interactive Sankey →

Source: Integra Lifesciences Holdings 10-Q on SEC EDGAR.